Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alexza Pharmaceuticals, Inc.
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document.
Diagnosis of cyclic vomiting syndrome (CVS) using the Rome IV diagnostic criteria.
Otherwise healthy, as determined by the responsible physician, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit
Negative urine tests for selected drugs of abuse and alcohol breath test at Screening.
You may not be if
Any significant medical or psychiatric condition that could, in the Investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol.
Any condition, including the presence of laboratory abnormalities or pulmonary condition, which according to the Investigator places the subject at unacceptable risk if he/she were to participate in the study.
A diagnosis of any gastrointestinal disorder other than CVS that in the judgement of the Investigator could compromise the subject's safety or interfere with the interpretation of safety or efficacy data.
Clareo Health | Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
